Clinical and Translational Allergy最新文献

{"title":"Food Allergy Diagnosis in Early Childhood: Journey Mapping Study With Parents and Pediatricians","authors":"Madlen Hörold,&nbsp;Magdalena Rohr,&nbsp;Christian Apfelbacher,&nbsp;Susanne Brandstetter","doi":"10.1002/clt2.70158","DOIUrl":"10.1002/clt2.70158","url":null,"abstract":"<p>Food allergy (FA) in early childhood can be challenging for families, even before a diagnosis is made, as parents often experience anxiety and have to change their routines. Research integrating parental and pediatrician perspectives during the pre-diagnostic phase is scarce. This study aimed to develop a journey map illustrating the FA pre-diagnostic process in early childhood from both perspectives. We triangulated 30 transcripts (16 parent interviews; 11 interviews and three focus groups with pediatricians) from two qualitative studies within the Food Allergy Biomarker Application Consortium (NAMIBIO App) using qualitative content analysis and data visualization. Four phases emerged: (non-)awareness, suspicion, healthcare seeking, and diagnostics. Parents were often unaware of FA risks, even with risk factors present. Pediatricians hesitated to address FA risk proactively, due to lacking specific guideline recommendations and concerns about triggering parental health-related anxiety. Both parents and pediatricians mentioned gaps in communication between pediatricians and midwives. During the suspicion phase, families searched for information or adjusted feeding practices while symptoms were often vague. Healthcare seeking often involved lengthy referrals. Pediatricians reported knowledge gaps among colleagues regarding FA. In the diagnostic phase, parents perceived delays in diagnosis; pediatricians mentioned limited resources, particularly for oral food challenges. Integrating both perspectives revealed shared concerns and different views on how to improve the process. Key intervention points to improve the pre-diagnostic process include clear, up-to-date guidelines, risk communication and improved interdisciplinary collaboration to reduce uncertainty and promote parental confidence.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Killer Cell Dysfunction Causes Eosinophil Accumulation in Chronic Rhinosinusitis With Nasal Polyps","authors":"Yohei Sato,&nbsp;Daiki Nakashima,&nbsp;Natsuki Inoue,&nbsp;Erika Osada,&nbsp;Tomomitsu Hirota,&nbsp;Yasuhiro Tsunemi,&nbsp;Nobuyoshi Otori,&nbsp;Mamoru Yoshikawa,&nbsp;Mayumi Tamari,&nbsp;Tsuguhisa Nakayama","doi":"10.1002/clt2.70156","DOIUrl":"10.1002/clt2.70156","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;Chronic rhinosinusitis with nasal polyps (CRSwNP), a chronic nasal and sinonasal inflammatory disease, is characterized by nasal obstruction, nasal discharge, and olfactory disturbances persisting for more than 12 weeks [&lt;span&gt;1&lt;/span&gt;]. Notably, although CRSwNP is predominantly characterized as a type 2 inflammation, it may involve mixed inflammatory endotypes, including type 1 and 3 inflammation, with notable regional differences in endotype composition [&lt;span&gt;2&lt;/span&gt;]. Whereas natural killer (NK) cell dysfunction may contribute to eosinophil proliferation in CRSwNP, the lack of immune phenotype and gene expression profiles of nasal polyp (NP)-derived NK cells currently limits further characterization [&lt;span&gt;3, 4&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Recently, NK cells have been considered regulators of allergic reactions in atopic dermatitis [&lt;span&gt;5&lt;/span&gt;], and transcriptomic profiles of atopic skin-derived immune cells have revealed a distinct subtype of atopic dermatitis based on eosinophil infiltration, with dual blockade of interleukin (IL)-4 and IL-13 enhancing NK cell signatures [&lt;span&gt;6&lt;/span&gt;]. Furthermore, the innate NK–eosinophil immune crosstalk has shown that NK cells can suppress eosinophils through NKp46 and NKp30 upon activation [&lt;span&gt;7&lt;/span&gt;]. Reportedly, CRSwNP-derived NK cells exhibit reduced expression of functional receptors [&lt;span&gt;8&lt;/span&gt;]. Herein, we performed transcriptomic analysis and immune cell profiling to investigate the interactions between NK cells and eosinophils, focusing in particular on NK cell phenotype and function. Furthermore, to assess the eosinophil apoptosis induction by NK cells, we co-cultured these two cell types.&lt;/p&gt;&lt;p&gt;Collagenase digestion was used to isolate immune cells from freshly harvested surgical NP samples of multiple donors (&lt;i&gt;n&lt;/i&gt; = 26), and cells were sorted and analyzed by flow cytometry (Figure 1A–C; Supporting Information S1: Figure S1; Supporting Information S2: Table S1). Through unbiased clustering, eosinophil-high (Eos&lt;sup&gt;high&lt;/sup&gt;)- and eosinophil-low (Eos&lt;sup&gt;low&lt;/sup&gt;)-infiltrated NPs were grouped, with the eosinophil vector being the predominant factor (Figure 1D,E). NP subtype was determined based on eosinophil percentage (Eos&lt;sup&gt;high&lt;/sup&gt;-infiltrated NPs: 36% ± 9%, Eos&lt;sup&gt;low&lt;/sup&gt;-infiltrated NPs: 8% ± 6%; &lt;i&gt;p&lt;/i&gt; &lt; 0.0001), and it was found that the percentages of other immune cells were reduced in Eos&lt;sup&gt;high&lt;/sup&gt;-infiltrated NPs (Figure 1F). Whereas the proportions of T-cells, NK cells, and neutrophils significantly reduced, the proportions of B-cells or monocytes in Eos&lt;sup&gt;high&lt;/sup&gt;-infiltrated NPs did not significantly reduce (Supporting Information S1: Figure S2). Moreover, we detected notable differences in the whole-transcriptome profiles of NK cells, which differed in Eos&lt;sup&gt;high&lt;/sup&gt;- and Eos&lt;sup&gt;low&lt;/sup&gt;-infiltrated NPs (Figure 2A). Interestingly, compared with those in Eos&lt;sup&gt;low&lt;/sup&gt;-infiltrated NPs, Eos&lt;sup&gt;high&lt;/sup&gt;-infiltrated NPs","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Higher Prevalence of Dupilumab-Induced Ocular Adverse Events in Atopic Dermatitis Compared to Asthma: A Daily Practice Analysis”","authors":"","doi":"10.1002/clt2.70154","DOIUrl":"10.1002/clt2.70154","url":null,"abstract":"<p>A. R. Schlösser, L. Bult, J. C. Thelen, et al., “Higher Prevalence of Dupilumab-Induced Ocular Adverse Events in Atopic Dermatitis Compared to Asthma: A Daily Practice Analysis,” <i>Clinical and Translational Allergy</i> (2024): e12386, https://doi.org/10.1002/clt2.12386.</p><p>In the results of the Abstract section, the text ‘Additionally, 20% of AD and <b>17.6%</b> of SA patients discontinued dupilumab treatment…’ was incorrect. The correct value for SA patients should be <b>8.6%</b> instead of 17.6%. This is accurately reflected later in the main text. Fortunately, this typo does not affect any conclusions or other major aspects of the article, and the overall findings remain unchanged.</p><p>We apologize for this error.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70154","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146206367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-Onset Compared to Childhood-Onset Asthma: Multifaceted Symptoms, Comorbidity, and Healthcare Burden","authors":"Reshed Abohalaka,&nbsp;Selin Ercan,&nbsp;Lauri Lehtimäki,&nbsp;Daniil Lisik,&nbsp;Saliha Selin Ozuygur Ermis,&nbsp;Helena Backman,&nbsp;Madeleine Rådinger,&nbsp;Bright I. Nwaru,&nbsp;Hannu Kankaanranta","doi":"10.1002/clt2.70160","DOIUrl":"10.1002/clt2.70160","url":null,"abstract":"<p>In this study, we compared symptoms, comorbidities, and healthcare burden between childhood-onset asthma (&lt; 18 years) and early adult-onset (18–39 years) and late adult-onset asthma (≥ 40 years). Among 3546 participants with data on physician-diagnosed asthma and onset age, 46.4% were defined as adult-onset [864 (24.4%) had early adult-onset asthma (18–39 years) and 782 (22.1%) had late adult-onset asthma (≥ 40 years)], which, compared to childhood-onset asthma, presented with more complex, multi-symptom profiles, including productive cough, sputum production, but less wheezing. Allergy-related comorbidities were more common in childhood-diagnosed asthma, while chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, obesity, and chronic sinusitis were more common in adult-onset asthma. Adult-onset asthma also had a higher disease burden, with more frequent medication use and exacerbations. Adult-onset asthma has an underlying complexity, contributing to a vicious cycle of worsening symptoms, increased medication use, and more comorbidities.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Safety of Japanese Cedar Pollen Sublingual Immunotherapy Tablets: A Post-Marketing Survey","authors":"Minoru Gotoh,&nbsp;Yuriko Maekawa,&nbsp;Tsuyoshi Ando,&nbsp;Noboru Kato,&nbsp;Eiji Horikawa,&nbsp;Noriaki Nishino","doi":"10.1002/clt2.70157","DOIUrl":"10.1002/clt2.70157","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Japanese cedar (JC) pollen sublingual immunotherapy (SLIT)-tablets (5000 Japanese allergy units [JAU]) are licensed for the treatment of JC-pollinosis with no age restriction on the basis of the results of a 5-year clinical trial. However, there have been no large-scale surveys of 5000 JAU in an actual clinical setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a multicenter observational prospective study. We assessed the safety and effectiveness of the long-term use of 5000 JAU in patients with JC-pollinosis, with an observation period of two seasons of JC pollen dispersal, at clinical sites in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our safety analysis included 516 patients and the effectiveness analysis included 469 patients. Adverse drug reactions (ADRs) occurred in 68 patients (13.18%) and mainly comprised administration site-related events that occurred during the early phase of administration. Treatment discontinuation due to ADRs occurred in 18 patients (3.49%). No deaths, anaphylactic shock, or serious ADRs occurred. Regarding effectiveness, the severity of JC-pollinosis was rated as “almost asymptomatic + mild” in 82.19% of patients in Season 1 and 92.58% in Season 2. Quality of life was rated as “score 0 (Fine) + 1” in 75.83% of patients in Season 1 and 86.09% in Season 2. Overall improvement was rated as “improved + slightly improved” in 95.68% of patients in Season 1 and 96.38% in Season 2 following the initiation of JC pollen SLIT-tablets. Nasal and ocular symptom scores also decreased with increasing treatment duration. Treatment continuation rates were 89.53% in Season 1 and 78.29% in Season 2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The JC pollen SLIT-tablets appear to be safe and effective in an actual clinical setting during two seasons. No new safety or effectiveness issues were identified, and no additional safety or effectiveness precautions were required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12904777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery","authors":"Thomas S. Higgins,&nbsp;Jennifer E. Douglas,&nbsp;Robert C. Kern,&nbsp;James N. Palmer,&nbsp;Sietze Reitsma,&nbsp;Martin Wagenmann,&nbsp;Rhea Goodman,&nbsp;Mark Corbett,&nbsp;Cristina Almansa,&nbsp;Amr Radwan","doi":"10.1002/clt2.70149","DOIUrl":"10.1002/clt2.70149","url":null,"abstract":"<p>Primary diffuse type 2-dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even safety. Mechanisms of smell loss in CRSwNP may be related to conductive losses due to significant burden of nasal polyps, as well as the impact of type 2 inflammatory mediators on olfactory sensory neurons. Initial medical management frequently involves intranasal or oral corticosteroids. Patients whose symptoms remain uncontrolled by medical treatment may be offered sinonasal surgery; however, patients may experience recurrence of smell loss following surgery. Guidelines recommend biologics for certain patients with CRSwNP after undergoing complete endoscopic sinus surgery, and data from clinical trials and real-world evidence support their effectiveness in improving sense of smell. Given the impact of smell loss, shared decision-making is important in identifying treatment options best suited to achieving patient goals. This review provides an overview of the importance of smell loss in CRSwNP and its known mechanisms, and reviews the evidence for the efficacy of current treatment options in restoring sense of smell.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146092267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)","authors":"Isam Alobid,&nbsp;Sven F. Seys,&nbsp;Joost de Kinderen,&nbsp;Valérie Hox,&nbsp;Carlo Cavaliere,&nbsp;Alexandros Andrianakis,&nbsp;Sven Schneider,&nbsp;Martin Wagenmann,&nbsp;Martin Bruch,&nbsp;Adriana Izquierdo-Domínguez,&nbsp;Xavier Gonzalez-Compta,&nbsp;Laura Pardo Muñoz,&nbsp;Laura Van Gerven,&nbsp;Peter W. Hellings,&nbsp;Geoffrey Mortuaire,&nbsp;Martin Burian,&nbsp;Mireia Golet-Fors,&nbsp;Mathilde Moyaert,&nbsp;Peter-Valentin Tomazic,&nbsp;Giulia Bettio,&nbsp;Marco de Vincentiis,&nbsp;Zuzana Diamant,&nbsp;Julia Eckl-Dorna,&nbsp;Gert Mariën,&nbsp;Simonetta Masieri,&nbsp;Christina Morgenstern,&nbsp;Kathrin Scheckenbach,&nbsp;Aldine Tu,&nbsp;Camilo Rodriguez van Strahlen,&nbsp;Claus Bachert,&nbsp;CHRINOSOR consortium","doi":"10.1002/clt2.70153","DOIUrl":"10.1002/clt2.70153","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to evaluate mepolizumab effectiveness in a real-world cohort from 12 tertiary centers in 6 European countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>A retrospective analysis was conducted in 110 CRSwNP patients (comorbid asthma: 86.4%). CRS-related outcomes were analyzed at baseline, 24 and 52 weeks of mepolizumab. Treatment response was evaluated based on EUFOREA 2021 criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significant improvements in NPS, Sinonasal Outcome Test-22 (SNOT-22), and visual analog scale (VAS) symptom scores were observed at 24 and 52 weeks compared to baseline. Further improvement between weeks 24 and 52 was observed for NPS and SNOT-22. Asthma Control Test (ACT) also improved significantly by week 24 (ACT score ≥ 20: 64.5%). At least one response criterion (change in SNOT-22 ≥ 8.9, NPS ≥ 1, VAS total sinus symptoms ≥ 20, VAS nasal blockage ≥ 20, VAS loss of smell ≥ 20) was met by 85.6% and 78.7% of patients at 24 and 52 weeks, respectively. A more stringent composite response (SNOT-22 &lt; 30, NPS &lt; 4, VAS total sinus symptoms &lt; 50, and VAS nasal blockage &lt; 50) was achieved in 18.3% and 44.6% of patients at 24 and 52 weeks, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Mepolizumab demonstrated clinically meaningful benefits in a real-world CRSwNP population, with nearly half of patients achieving a beneficial composite treatment response by week 52. Notably, progressive improvements between weeks 24 and 52 underscore the value of prolonged therapy and the importance of evaluating treatment response at one year.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 2","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12860572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146096653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema","authors":"Aaron Yarlas,&nbsp;Alexandra J. Feld,&nbsp;Jakob B. Bjorner,&nbsp;Cary Thurm,&nbsp;Laura Bordone,&nbsp;Kenneth B. Newman,&nbsp;Sabrina Treadwell,&nbsp;Danny M. Cohn","doi":"10.1002/clt2.70143","DOIUrl":"10.1002/clt2.70143","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hereditary angioedema (HAE), defined by unpredictable, painful, acute swelling attacks affecting several bodily locations, diminishes patients' quality of life. Assessing disease activity, burden, and treatment response pose challenges in routine care. The patient-reported Angioedema Control Test (AECT) is a subjective measure of HAE disease control. Criterion validity of AECT with objective measures of disease control has not been previously assessed. This study evaluates the criterion validity of AECT using investigator-confirmed HAE attack rate in patients with HAE.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Phase 3 OASIS-HAE study (NCT05139810) randomized patients with HAE to receive donidalorsen 80 mg or placebo subcutaneously for 24 weeks. The full analysis population included all dosed patients (<i>N</i> = 90), pooled across treatment arms. This post-hoc analysis examined the correlation between AECT and HAE attacks at Baseline, 12, and 24 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>AECT scores correlated moderately to strongly with HAE attack rate (<i>ρ</i> = −0.40 to −0.85). Mean attack rates differed significantly between poor (AECT &lt; 10) and well-controlled (AECT ≥ 10) disease subgroups at study visits. At Week 24, 97.4% of patients reporting complete disease control (AECT maximum score of 16) had an attack rate of 0; the remaining patient had 1 attack. Patients with no attacks had a mean AECT score of 15.1 versus 7.7 for patients with attack rates &gt; 0.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study supports the criterion validity of AECT in patients with HAE scores. AECT scores were strongly associated with objective disease control. AECT may be a valuable tool for monitoring disease control in patients with HAE.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tezepelumab Improves Small Airways Dysfunction in Severe Asthma: A 52-Week Real-World Study","authors":"Francesco Menzella,&nbsp;Marcello Cottini,&nbsp;Elena Parazzini,&nbsp;Rory Chan,&nbsp;Laura Ventura,&nbsp;Michele Mondoni,&nbsp;Annamaria Bosi,&nbsp;Michela Bortoli,&nbsp;Gianenrico Senna,&nbsp;Carlo Lombardi,&nbsp;Lorenzo Corsi,&nbsp;Silvia Tonin,&nbsp;Andrea Rastelli,&nbsp;Cristina Albrici,&nbsp;Giulia Carone,&nbsp;Maria Sartor,&nbsp;Tatiana Scandiuzzi Piovesan,&nbsp;Maria Rita Marchi","doi":"10.1002/clt2.70147","DOIUrl":"10.1002/clt2.70147","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;Small airway dysfunction (SAD) is a critical trait in severe asthma (SA), driving exacerbation risk and oral corticosteroid (OCS) dependence, yet it often remains undetected by conventional spirometry [&lt;span&gt;1&lt;/span&gt;]. Advanced techniques, such as oscillometry, now allow for its non-invasive assessment in clinical practice. Tezepelumab, a monoclonal antibody that blocks the upstream alarmin TSLP, has demonstrated broad efficacy across SA phenotypes by targeting alarmins high up in the inflammatory cascade [&lt;span&gt;2&lt;/span&gt;]. However, its long-term, real-world impact on SAD remains insufficiently defined except for preliminary remarks [&lt;span&gt;3&lt;/span&gt;]. We aimed to evaluate the 52-week effectiveness of tezepelumab in a cohort of 27 SA patients stratified by SAD and Type 2 (T2) inflammatory status.&lt;/p&gt;&lt;p&gt;This prospective, multicentre, real-world study included 27 consecutive adult subjects with SA. At baseline, patients were stratified according to the presence of SAD, defined as inspiratory or expiratory reactance values below the lower limit of normal, and by T2 status, with T2-high defined as blood eosinophil count (BEC) &gt; 150 cells/μL and/or fractional exhaled nitric oxide (FeNO) &gt; 20 ppb. All outcomes were assessed at baseline, 6 and 12 months. Adherence to 4-weekly subcutaneous administration and follow-up visits was strictly monitored through hospital pharmacy dispensation records and scheduled clinical visits at baseline, 6, and 12 months.&lt;/p&gt;&lt;p&gt;Statistical analysis were conducted using non-parametric tests owing to the small sample size (&lt;i&gt;N&lt;/i&gt; = 27) and non-normal dat distribution, as assessed by the Shapiro–Wilk test. Differences between independent groups (SAD vs. non-SAD) were evaluated using the Mann–Whitney &lt;i&gt;U&lt;/i&gt; test. Associations between categorical variables were analyzed using chi-squared or Fisher's exact tests. Longitudinal changes across time points (baseline vs. 6 vs. 12 months) were assessed using the Friedman test. Categorical variables were compared using Fisher's exact test. A two-sided &lt;i&gt;p&lt;/i&gt; value &lt; 0.05 was considered statistically significant. At baseline, 48% of the cohort exhibited SAD. These patients displayed significantly lower forced expiratory volume in 1 s (FEV&lt;sub&gt;1&lt;/sub&gt;) and forced vital capacity (FVC; Supporting Information S1: Table S1), higher total airway resistance (Rrs5), and more abnormal reactance at 5 Hz (Xrs5) and reactance area (AX) compared to the non-SAD group (Supporting Information S1: Table S2; Table 1).&lt;/p&gt;&lt;p&gt;Treatment with tezepelumab led to an improvement of ACT score by 6 points at 12 months, while the Asthma Quality of Life Questionnaire (AQLQ) score increased by 1.0 unit, both exceeding the minimal clinically important difference by a factor of two (Table 2, Figure S1). Tezepelumab induced a marked reduction in annualized exacerbation rates and maintenance OCS (mOCS) use across all phenotypes (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). By 12 months, mOCS was discontinued","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Haptoglobin as a Predictor of Treatment Response in Patients With Chronic Spontaneous Urticaria","authors":"Kun-Woo Park,&nbsp;Boyoun Choi,&nbsp;Da-Hye Moon,&nbsp;Se-Min Park,&nbsp;Young-Min Ye","doi":"10.1002/clt2.70148","DOIUrl":"10.1002/clt2.70148","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic spontaneous urticaria (CSU) is a mast cell-driven disease associated with systemic inflammation and altered immune responses. Haptoglobin (HP), an acute-phase glycoprotein, exhibits antioxidative and immunomodulatory properties, while zonulin, the precursor of HP-2, regulates epithelial barrier integrity. We investigated the clinical relevance of serum HP and zonulin in CSU and their association with treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum HP and zonulin levels were measured by ELISA in 124 CSU patients and 57 healthy controls (HCs). In 62 CSU patients, follow-up samples were obtained after 3 months of treatment. Clinical outcomes included the urticaria activity score over 7 days (UAS7) and the urticaria control test (UCT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Serum HP levels were significantly higher in CSU patients than in HCs (median 1145.1 vs. 839.2 μg/mL, <i>p</i> &lt; 0.001), whereas zonulin levels did not differ. HP correlated positively, but weakly, with the white blood cell count, C3 and C-reactive protein (all rho ≈ 0.2), and negatively with disease duration and eosinophil percentage. Zonulin correlated negatively with UCT scores but not with HP. After treatment, HP decreased significantly (<i>p</i> &lt; 0.001), with greater reductions in patients showing a ≥ 12-point improvement on the UAS7. Baseline HP was higher in patients who achieved complete control (UCT = 16) than others (<i>p</i> = 0.017). ROC analysis identified baseline HP ≥ 1249 μg/mL as an optimal cutoff, confirmed as an independent predictor of complete control (odds ratio = 4.23, <i>p</i> = 0.029).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum HP is elevated in CSU patients, decreases with treatment, and independently predicts complete urticaria control. HP may serve as a potentially prognostic biomarker for CSU.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 1","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12777545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}